Imipridone enhances vascular relaxation via FOXO1 pathway
- 1 November 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (11) , 1816-1823
Abstract
Cardiovascular complications are a side effect of cancer therapy, potentially through reduced blood vessel function. ONC201 (TIC10) is currently used in phase 2 clinical trials to treat high-grade gliomas. TIC10 is a phosphatidylinositol 3-kinase (PI3K)/AKT/extracellular signal-regulated kinase (ERK) inhibitor that induces apoptosis via upregulation of TNF-related apoptosis-inducing ligand, which via stimulation of FOXO and death receptor could increase eNOS upregulation. This has the potential to improve vascular function through increased NO bioavailability. Our aim was to investigate the role of TIC10 on vascular function to determine if it would affect the risk of CVD. Excised abdominal aorta from White New Zealand male rabbits were cut into rings. Vessels were incubated with TIC10 and AS1842856 (FOXO1 inhibitor) followed by cumulative doses of acetylcholine (Ach) to assess vessel function. Vessels were then processed for immunohistochemistry. Incubation of blood vessels with TIC10 resulted in enhanced vasodilatory capacity. Combination treatment with the FOXO1 inhibitor and TIC10 resulted in reduced vascular function compared to control. Immunohistochemical analysis indicated a 3-fold increase in death receptor 5 (DR5) expression in the TIC10-treated blood vessels but the addition of the FOXO1 inhibitor downregulated DR5 expression. The expression of DR4 receptor was not significantly increased in the presence of TIC10; however, addition of the FOXO1 inhibitor downregulated expression. TIC10 has the capacity to improve the function of healthy vessels when stimulated with the vasodilator Ach. This highlights its therapeutic potential not only in cancer treatment without cardiovascular side effects, but also as a possible drug to treat established CVD.Keywords
This publication has 31 references indexed in Scilit:
- Immunity, atherosclerosis and cardiovascular diseaseBMC Medicine, 2013
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor EffectsScience Translational Medicine, 2013
- FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2Cardiovascular Research, 2012
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient miceAtherosclerosis, 2011
- Activation of the Akt Survival Pathway Contributes to TRAIL Resistance in Cancer CellsPLOS ONE, 2010
- FOXOs, cancer and regulation of apoptosisOncogene, 2008
- SIRT1 controls endothelial angiogenic functions during vascular growthGenes & Development, 2007
- AKT Participates in Endothelial Dysfunction in HypertensionCirculation, 2004
- FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand ExpressionJournal of Biological Chemistry, 2002